On Friday, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) was 4.27% up from the session before settling in for the closing price of $13.12. A 52-week range for DAWN has been $9.67 – $18.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -19.34%. With a float of $60.61 million, this company’s outstanding shares have now reached $87.23 million.
The extent of productivity of a business whose workforce counts for 155 workers is very important to gauge.
Day One Biopharmaceuticals Inc (DAWN) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Day One Biopharmaceuticals Inc stocks. The insider ownership of Day One Biopharmaceuticals Inc is 30.65%, while institutional ownership is 73.25%. The most recent insider transaction that took place on Jun 21 ’24, was worth 131,877. In this transaction Director of this company sold 10,000 shares at a rate of $13.19, taking the stock ownership to the 40,485 shares. Before that another transaction happened on Jun 10 ’24, when Company’s HEAD OF R&D sold 30,000 for $12.62, making the entire transaction worth $378,588. This insider now owns 1,141,081 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -19.34% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
You can see what Day One Biopharmaceuticals Inc (DAWN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.49, a number that is poised to hit -0.75 in the next quarter and is forecasted to reach -2.15 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
The latest stats from [Day One Biopharmaceuticals Inc, DAWN] show that its last 5-days average volume of 1.06 million was superior to 0.88 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 80.93%. Additionally, its Average True Range was 0.79.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 28.39%, which indicates a significant decrease from 85.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.03% in the past 14 days, which was lower than the 67.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.69, while its 200-day Moving Average is $13.88. Now, the first resistance to watch is $14.14. This is followed by the second major resistance level at $14.59. The third major resistance level sits at $15.21. If the price goes on to break the first support level at $13.07, it is likely to go to the next support level at $12.45. The third support level lies at $12.00 if the price breaches the second support level.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
There are 87,390K outstanding shares of the company, which has a market capitalization of 1.20 billion. As of now, sales total 0 K while income totals -188,920 K. Its latest quarter income was 0 K while its last quarter net income were -62,410 K.
